August 8, 2026 · Gynecologic oncology reports · DOI: 10.1016/j.gore.2026.102175

Rescuing a refractory Leiomyosarcoma: ALK-DCTN1 fusion as a gateway to long-term control with Ceritinib

Listen to this summary

The authors aim to highlight the potential of targeting rare molecular alterations, specifically the ALK-DCTN1 fusion, in advanced uterine leiomyosarcoma (uLMS) to improve treatment outcomes. They present a case of a 59-year-old woman with stage IV uLMS who achieved significant tumor regression and durable partial remission after treatment with the ALK inhibitor ceritinib, following multiple failed conventional therapies. This case emphasizes the critical role of comprehensive molecular profiling in identifying actionable targets for effective treatment in aggressive malignancies like uLMS.

Francis Yew Fu Tieng, Sri Kisha Subramaniam, Po Lin Ooi

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play